Refractory pancytopenia upon initiation of asciminib in tyrosine kinase inhibitor-resistant chronic myeloid leukemia

Asciminib, a “Specifically Targeting the ABL Myristoyl Pocket” inhibitor, is a new drug in the treatment of tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML). Hemocytopenias associated with asciminib are common adverse events documented by clinical trials. We report a case of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tessier, Steven, Aiad, Mina, Longo, Santo, Wilson, Melissa, Faroun, Yacoub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401557/
https://www.ncbi.nlm.nih.gov/pubmed/37547190
http://dx.doi.org/10.4103/ijciis.ijciis_85_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401557/
https://www.ncbi.nlm.nih.gov/pubmed/37547190
http://dx.doi.org/10.4103/ijciis.ijciis_85_22

Ejemplares similares